Related Experiment Video
Updated: Mar 26, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
CYP2E1 RsaI/PstI polymorphisms contributed to oral cancer susceptibility: a meta-analysis
Yang Guo1, Shan Zhou2, Feng Liu3
1Department of Endodontics, The 2nd Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang, China.
Abstract:
Several studies have investigated the associations between CYP2E1 RsaI/PstI polymorphisms and oral cancer risk, but results have been inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. PubMed and China National Knowledge Infrastructure (CNKI) searches were carried out for relevant studies published before September 2014. Meta-analysis was performed with the Stata, version 11.0. A total of 14 case control studies, including 1,962 cases and 3,271 controls, were selected. Overall, significant association was found between the CYP2E1 RsaI/PstI polymorphisms and oral cancer risk (for c1c1 vs. c1c2, OR=0.72, 95% CI=0.56-0.91; for c1c1 vs. c2c2, OR=0.45, 95% CI=0.25-0.82), while not for the dominant model (c1c1 vs. c1c2+c2c2, OR=0.84, 95% CI=0.69-1.01). In the subgroup analysis by ethnicity, statistically significant association was found in Caucasian, East Asian and South Asian. This meta-analysis suggests that the CYP2E1 RsaI/PstI polymorphisms are a risk factor for developing oral cancer.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
The Ras Gene
Ras is a...

